David Grainger

From Wikipedia, the free encyclopedia
David Grainger
Born (1966-10-12) October 12, 1966
Alma mater Cambridge University
Occupation venture capitalist, Index Ventures, consultant, blogger

David Grainger is a partner at Index Ventures, a global venture capital firm with offices in London, Geneva and San Francisco,[1] in the firm’s life sciences practice.[2] He is also a partner at TCP Innovations, a life sciences consultancy,[3] and a blogger on topics related to the pharmaceutical industry under the pen name “DrugBaron”.[2]

Education

Reared in England, Grainger graduated with degree in Natural Sciences (Biochemistry) from Cambridge University in 1989, and a PhD in Vascular Cell Biology from the same institution in 1992.[4]

Career

After receiving his PhD, Grainger undertook post-doctoral research in the British Heart Foundation Smooth Muscle Cell laboratory at Cambridge University.[5] Following publications in Nature[6] and elsewhere[7] setting out his Protective Cytokine Hypothesis explaining the role of the cytokine TGF-beta 1 in the cardiovascular system,[8] Grainger was appointed principal investigator in the Department of Medicine at his alma mater, Cambridge University, in 1997.[9]

While at Cambridge University, Grainger founded life sciences companies including FingerPrint Diagnostics (2001),[10] and Funxional Therapeutics (2005).[11] FingerPrint Diagnostics merged with SmartBead Technologies to form Pronostics, a molecular diagnostics company, in 2006.[12][10]Funxional Therapeutics, based on an anti-inflammatory drug candidate spun-out from Grainger's Cambridge University lab, became an Index Ventures portfolio company where Grainger also served as chief scientific officer[11] until it was sold to Boehringer Ingelheim in 2012.[13]

Grainger joined Index Ventures in 2012.[3] At Index Ventures he has been involved with funding and advising a variety of companies, including XO1,[14] a biotech company developing an anticoagulant, where he served as interim chief executive and currently serves as chairman.[15] [16]

Publications and Patents

Grainger has co-authored a number of papers in peer-reviewed scientific journals,[17] including Nature,[6] Science[18] and Nature Medicine.[19]

While Grainger frequently blogs under the pen name “DrugBaron” on a range of topics related to the pharmaceutical industry, he is particularly known for his views on lean start-ups.[2][3] A DrugBaron post on 10 December 2013 was subsequently discussed in a Forbes.com article, “To Save Pharma R&D, David Grainger Says Drug Developers Must Think Like CEOs of Lean Startups”.[2] Grainger is listed as an inventor on a number of patents.[20]

References

  1. ↑ "Index Ventures Raises $442 Million in New Fund". New York Times Dealbook. June 17, 2012. 
  2. ↑ 2.0 2.1 2.2 2.3 "To Save Pharma R&D, David Grainger Says Drug Developers Must Think Like CEOs Of Lean Startups". Forbes.com. December 14, 2013. 
  3. ↑ 3.0 3.1 3.2 "Is Big Pharma Learning from Its Late-Stage R&D Setbacks?". Forbes.com. June 7, 2013. 
  4. ↑ "BusinessWeek profile: David Grainger". 
  5. ↑ "Heart Disease Breakthrough Claimed". Nature Medicine. November 25, 2002. 
  6. ↑ 6.0 6.1 Grainger, David (1994). "Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice". Nature 370: 460. doi:10.1038/370460a0. 
  7. ↑ Grainger, David (2007). "TGF-β and atherosclerosis in man". Cardiovascular Research 74: 213. doi:10.1016/j.cardiores.2007.02.022. 
  8. ↑ Grainger DJ (2005). "Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis". Arterioscler. Thromb. Vasc. Biol. 24 (3): 399–404. doi:10.1161/01.ATV.0000114567.76772.33. PMID 14699019. 
  9. ↑ "Index Ventures backs novel anticoagulant". Mednous. June 17, 2013. 
  10. ↑ 10.0 10.1 "Cambridge merger creates Pronostics". Biotech Business week. August 7, 2006. 
  11. ↑ 11.0 11.1 "Boehringer Ingelheim acquires Funxional products". thepharmaletter. July 24, 2012. 
  12. ↑ "Revolutionary Coronary Test Ends Heartache for Patients and NHS". BusinessWeekly. January 31, 2007. 
  13. ↑ "Boehringer buys PhII respiratory drug program". FierceBiotech. July 23, 2012. 
  14. ↑ "XO1 Cracks Coagulation Conundrum, Raises $11M". BioWorld News. June 16, 2013. 
  15. ↑ "XO1 Raises $11M From Index Ventures to Develop Anticoagulant Drug". Dow Jones. June 17, 2013. 
  16. ↑ "Index Ventures Invests $11 Million on Clot-Busting Drug". Bloomberg News. June 16, 2013. 
  17. ↑ "Google Scholar search: David J. Grainger". 
  18. ↑ Grainger, D.J. (1993). "Proliferation of human smooth muscle cells promoted by lipoprotein(a)". Science 260: 1655. doi:10.1126/science.8503012. 
  19. ↑ Brindle, Joanne (2002). "Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics". Nature Medicine: 1439. doi:10.1038/nm1202-802. 
  20. ↑ "Google patent search: David Grainger". 

External links

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.